EODData

MEMBERSHIP REGISTER LOG IN

FRA, E08A: Exagen Inc

23 Dec 2025
LAST:

5.500

CHANGE:
 0.30		OPEN:
5.500		HIGH:
5.500		ASK:
0.000		VOLUME:
230
CHG(%):
5.77		PREV:
5.200		LOW:
5.500		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
23 Dec 255.5005.5005.5005.500230
22 Dec 255.2005.2005.2005.200230
19 Dec 255.4005.4005.4005.400230
18 Dec 255.3505.3505.3505.350230
17 Dec 255.6505.6505.6505.650230
16 Dec 255.8505.8505.8505.850230
15 Dec 255.9505.9505.9505.950230
12 Dec 256.0006.0006.0006.000230
11 Dec 255.9505.9505.9505.950230
10 Dec 255.9005.9005.9005.900230

PROFILE

Name:Exagen Inc
About:Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Sector:Healthcare
Address:1261 Liberty Way, Vista, CA, United States, 92081
Website:https://www.exagen.com
ISIN:US30068X1037
LEI:549300JV2CYDOME5OO17

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-12.05 
Forward P/E:-5.52 
PEG Ratio:-0.39 
Price to Sales:3.79 
Price to Book:10.46 
Profit Margin:-0.29 
Operating Margin:-0.15 
Return on Assets:-0.16 
Return on Equity:-0.88 
Revenue:51.09M 
Shares:22.0M 
Market Cap:121.02M 

TECHNICAL INDICATORS

MA5:5.421.5%
MA10:5.683.2%
MA20:5.998.9%
MA50:7.7240.3%
MA100:8.0245.9%
MA200:6.6020.1%
STO9:37.50
STO14:27.27
RSI14:37.50 
WPR14:-72.73
MTM14:-0.65
ROC14:-0.11 
ATR:0.14 
Week High:5.856.4%
Week Low:5.205.8%
Month High:6.6520.9%
Month Low:5.2020.1%
Year High:10.2085.5%
Year Low:2.58113.5%